GSTM1, GSTT1, and GSTP1 polymorphism and lung cancer risk in relation to tobacco smoking |
| |
| Authors: | Schneider Joachim Bernges Ulrike Philipp Monika Woitowitz Hans-Joachim |
| |
| Institution: | 1. Center of Outcomes Research and Evaluation, Maine Medical Center Research Institute, Maine Medical Center, Portland, ME, USA;2. Department of Medicine, Maine Medical Center, Portland, ME, USA;3. Department of Geriatrics, Maine Medical Center, Portland, ME, USA;4. Institute for Clinical Evaluative Sciences, Sunnybrook Health Sciences Centre, Toronto, Canada;5. Cancer Therapy Evaluation Program, National Cancer Institute, Bethesda, MD, USA;6. Department of Gynecologic Oncology, Maine Medical Center, Portland, ME, USA;7. Applied Research Program, National Cancer Institute, Bethesda, MD, USA;2. Professor and Chairman, Department of Cell and Molecular Pharmacology, John C. West Chair of Cancer Research, Medical University of South Carolina, Charleston, South Carolina, USA;3. Department of Pharmaceutical and Biomedical Sciences, Medical University of South Carolina, Charleston, South Carolina, USA |
| |
| Abstract: | The impact of genetic polymorphisms in GSTM1, GSTP1 or GSTT1 on susceptibility to lung cancer has received particular interest since these enzymes play a central role in detoxification of major classes of tobacco carcinogens. In the current German study we investigated the role of GSTM1, GSTT1 and GSTP1 polymorphisms as a genetic modifier of risk for individuals with lung cancer as susceptible genotypes especially in relation to tobacco smoking. The GSTM1, the GSTP1 as well as GSTT1-polymorphism were determined by real time PCR analysis in 446 lung cancer patients and 622 controls. The observed allele frequencies of the GSTP1 polymorphism in the population were within the range described for Caucasians. Multivariate analyses of lung cancer patients, who carried at least one mutant variant allele of GSTP1 (OR=1.03; 95%-CI: 0.76-1.39) did not show any elevated risks. GSTM1 or GSTT1 null-genotypes were found in 47.3% resp. 18.5% of the controls and in 52.5% resp. 16.8% of the cancer patients. The estimated risk of the GSTM1 null genotype for lung cancer was OR=1.34 (95%-CI: 0.99-1.81) and for the GSTT1 null genotype OR=0.88 (95%-CI: 0.59-1.32). When analyzed by histology no individual subtype of lung cancer was strongly associated with the polymorphisms. Lung cancer risk rose significantly with higher cumulative cigarette consumption confirming the association with smoking-related lung cancer risk. Stratified analysis between tobacco smoking and variant genotypes revealed for heavy smokers (>60 pack-years) increasing risks at the presence for at least one copy of the GSTP1 variant allele OR=50.56 (95%-CI: 15.52-164.79). The corresponding risks for GSTM1 null genotypes were OR=112.08 (95%-CI: 23.02-545.71) and for the GSTT1 null-genotype OR=158.49 (95%-CI: 17.75-1415.06) in smokers >60 pack-years. Analysing the interaction between tobacco smoking and the genotypes, combined smoking and having the susceptible genotypes did not show a joint effect. In this study polymorphisms of the GSTM1, GSTT1 or GSTP1 had no relevant modifying effect on lung cancer risk and cumulative smoking dose. |
| |
| Keywords: | |
| 本文献已被 ScienceDirect PubMed 等数据库收录！ |
|
